Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
Department of Surgical Oncology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.
Eur J Surg Oncol. 2024 Mar;50(3):107976. doi: 10.1016/j.ejso.2024.107976. Epub 2024 Jan 28.
To perform surgical staging of early stage ovarian cancer (EOC), conventional laparoscopy (LS) and robot-assisted laparoscopy (RLS) appear to be reliable procedures compared to open surgery. But oncologicals results with long-term follow up are limited in the literature. The objective of this study is to evaluate the surgical and long-term survival for patients managed by minimally invasive surgery (MIS).
We conducted a multicentric retrospective study in 6 institutions. All patients referred for epithelial EOC (apparent stage I-IIa) managed with LS and RLS were involved.
From December 2008 to December 2017, 140 patients were included (109 in LS group and 31 in RLS group). A total of 27 (19.2 %) patients were upstaged to an advanced ovarian cancer (FIGO stage > IIA), and 73 % of patients received chemotherapy. Mean operative time was 265,8 ± 88,4 min and significantly longer in RLS group (LS = 254,5 ± 86,8; RLS = 305,6 ± 85,5; p = 0,008). Rate of severe post-operative complications (grade 3) was 5,7 %. Thirteen conversion to laparotomy occurred, including one per-operative hemorrhaege. After a mean follow-up of 60,7 months, 29 (20.7 %) patients recurred, with a time to recurrence was >24 months in 51,7 % of cases. Overall survival (OS) was 88.6 % and disease-free survival (DFS) was 79.3 %. Oncologic outcomes were similar between LS and RLS group (OS: p = 0,504 and DFS: p = 0,213).
Surgical staging of EOC by LS or RLS approach has long-term equivalent surgical and oncological approach. These results seem to be equivalent to open surgery according to literature review.
为了对早期卵巢癌(EOC)进行手术分期,与开腹手术相比,传统腹腔镜(LS)和机器人辅助腹腔镜(RLS)似乎是可靠的方法。但文献中关于长期随访的肿瘤学结果有限。本研究的目的是评估微创外科(MIS)管理的患者的手术和长期生存情况。
我们在 6 家机构进行了一项多中心回顾性研究。所有接受上皮性 EOC(明显 I-IIa 期)LS 和 RLS 治疗的患者均纳入研究。
2008 年 12 月至 2017 年 12 月,共纳入 140 例患者(LS 组 109 例,RLS 组 31 例)。共有 27 例(19.2%)患者被分期为晚期卵巢癌(FIGO 分期> IIA),73%的患者接受了化疗。手术时间平均为 265.8±88.4 分钟,RLS 组明显更长(LS=254.5±86.8;RLS=305.6±85.5;p=0.008)。严重术后并发症(3 级)发生率为 5.7%。13 例转为开腹手术,其中 1 例术中出血。中位随访 60.7 个月后,29 例(20.7%)患者复发,51.7%的病例复发时间>24 个月。总生存率(OS)为 88.6%,无病生存率(DFS)为 79.3%。LS 和 RLS 组的肿瘤学结果相似(OS:p=0.504 和 DFS:p=0.213)。
LS 或 RLS 方法对 EOC 的手术分期具有长期等效的手术和肿瘤学方法。根据文献复习,这些结果似乎与开腹手术相当。